For instance, in a phase 3 clinical trial, melanoma patients with BRAF V600E-mutated melanoma had higher clinical response rates to treatment with the BRAF inhibitor, vemurafenib, than the chemotherapy, dacarbazine [6]. The gene discussed is BRAF; the disease is melanoma.